Anti-CBPA5/ CPA5 functional antibody
Anti-CBPA5/ CPA5 functional antibody for cell culture, ELISA & in-vivo assay
Go to CPA5/CPA5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0815-Ab-1/ GM-Tg-hg-SE0815-Ab-2 | Anti-Human CPA5 monoclonal antibody | Human |
GM-Tg-rg-SE0815-Ab-1/ GM-Tg-rg-SE0815-Ab-2 | Anti-Rat CPA5 monoclonal antibody | Rat |
GM-Tg-mg-SE0815-Ab-1/ GM-Tg-mg-SE0815-Ab-2 | Anti-Mouse CPA5 monoclonal antibody | Mouse |
GM-Tg-cynog-SE0815-Ab-1/ GM-Tg-cynog-SE0815-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CPA5 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0815-Ab-1/ GM-Tg-felg-SE0815-Ab-2 | Anti-Feline CPA5 monoclonal antibody | Feline |
GM-Tg-cang-SE0815-Ab-1/ GM-Tg-cang-SE0815-Ab-2 | Anti-Canine CPA5 monoclonal antibody | Canine |
GM-Tg-bovg-SE0815-Ab-1/ GM-Tg-bovg-SE0815-Ab-2 | Anti-Bovine CPA5 monoclonal antibody | Bovine |
GM-Tg-equg-SE0815-Ab-1/ GM-Tg-equg-SE0815-Ab-2 | Anti-Equine CPA5 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0815-Ab-1/ GM-Tg-hg-SE0815-Ab-2; GM-Tg-rg-SE0815-Ab-1/ GM-Tg-rg-SE0815-Ab-2; GM-Tg-mg-SE0815-Ab-1/ GM-Tg-mg-SE0815-Ab-2; GM-Tg-cynog-SE0815-Ab-1/ GM-Tg-cynog-SE0815-Ab-2; GM-Tg-felg-SE0815-Ab-1/ GM-Tg-felg-SE0815-Ab-2; GM-Tg-cang-SE0815-Ab-1/ GM-Tg-cang-SE0815-Ab-2; GM-Tg-bovg-SE0815-Ab-1/ GM-Tg-bovg-SE0815-Ab-2; GM-Tg-equg-SE0815-Ab-1/ GM-Tg-equg-SE0815-Ab-2 |
Products Name | Anti-CPA5 monoclonal antibody |
Format | mab |
Target Name | CPA5 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CPA5 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0815-Ag-1 | Recombinant multi-species CBPA5/ CPA5 protein |
Target information
Target ID | GM-SE0815 |
Target Name | CPA5 |
Gene ID | 93979,74649,408212,702974,482257,101089089,511416,100071982 |
Gene Symbol and Synonyms | 4930430M09Rik,CPA5 |
Uniprot Accession | Q8WXQ8 |
Uniprot Entry Name | CBPA5_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000158525 |
Target Classification | N/A |
The target: CPA5, gene name: CPA5, also named as . Carboxypeptidases have functions ranging from digestion of food to selective biosynthesis of neuroendocrine peptides. Members of the A/B subfamily of carboxypeptidases, such as CPA5, contain an approximately 90-amino acid pro region that assists in the folding of the active carboxypeptidase domain. Cleavage of the pro region activates the enzyme (Wei et al., 2002 [PubMed 11836249]).[supplied by OMIM, Mar 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.